Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chimerix, Inc. stock logo
CMRX
Chimerix
$8.54
$8.54
$0.75
$8.55
$801.09M-0.172.88 million shsN/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
$1.65
-1.2%
$1.67
$0.63
$2.75
$89.29M0.961.12 million shs2.01 million shs
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$2.12
+0.5%
$2.18
$1.82
$3.09
$86.19M1.59140,735 shs38,553 shs
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.37
+0.4%
$0.37
$0.22
$3.37
$15.45M-0.413.16 million shs830,687 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chimerix, Inc. stock logo
CMRX
Chimerix
0.00%0.00%0.00%0.00%+801.32%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
+12.84%-30.42%-2.91%+87.87%+1.21%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
+0.96%-2.76%-2.31%-1.86%-17.58%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-10.58%-12.28%+11.85%+28.28%-88.66%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Chimerix, Inc. stock logo
CMRX
Chimerix
0.5504 of 5 stars
1.00.00.04.10.01.70.6
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
2.7492 of 5 stars
3.24.00.00.02.92.50.0
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
1.2139 of 5 stars
0.04.00.00.03.30.80.6
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.5297 of 5 stars
0.03.00.00.02.70.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Chimerix, Inc. stock logo
CMRX
Chimerix
2.00
Hold$8.53-0.08% Downside
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
2.40
Hold$7.00324.24% Upside
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
2.00
HoldN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CMRX, PRPH, MIST, and ORMP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/5/2025
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$5.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Chimerix, Inc. stock logo
CMRX
Chimerix
$212K3,778.71N/AN/A$2.17 per share3.94
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
$1M88.21N/AN/A$0.25 per share6.60
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$1.34M64.63N/AN/A$3.61 per share0.59
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$6.77M2.29N/AN/A$0.25 per share1.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Chimerix, Inc. stock logo
CMRX
Chimerix
-$82.10M-$0.99N/AN/AN/AN/A-50.78%-44.94%8/11/2025 (Estimated)
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-$41.52M-$0.78N/AN/AN/AN/A-329.85%-67.20%8/6/2025 (Estimated)
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-$19.06M-$0.44N/AN/AN/AN/A-11.34%-10.73%8/13/2025 (Estimated)
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$53.36M-$1.26N/AN/AN/AN/A-184.38%-64.59%8/13/2025 (Estimated)

Latest CMRX, PRPH, MIST, and ORMP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-$0.18N/AN/AN/AN/AN/A
8/13/2025N/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-$0.01N/AN/AN/AN/AN/A
8/13/2025Q2 2025
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$0.15N/AN/AN/A$3.55 millionN/A
5/20/2025Q1 2025
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$0.18-$0.12+$0.06$0.12$2.45 million$1.43 million
5/15/2025Q1 2025
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-$0.03-$0.19-$0.16-$0.19N/A$2.00 million
5/14/2025Q1 2025
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-$0.19-$0.31-$0.12-$0.31N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Chimerix, Inc. stock logo
CMRX
Chimerix
N/AN/AN/AN/AN/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
N/AN/AN/AN/AN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Chimerix, Inc. stock logo
CMRX
Chimerix
N/A
6.33
6.33
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
4.06
4.67
4.67
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/A
23.94
23.94
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.30
1.03
0.98

Institutional Ownership

CompanyInstitutional Ownership
Chimerix, Inc. stock logo
CMRX
Chimerix
45.42%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
86.18%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
12.73%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.45%

Insider Ownership

CompanyInsider Ownership
Chimerix, Inc. stock logo
CMRX
Chimerix
13.10%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
19.50%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
13.70%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Chimerix, Inc. stock logo
CMRX
Chimerix
9093.80 million78.15 millionOptionable
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
3053.46 million43.04 millionOptionable
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
1040.85 million35.25 millionOptionable
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
13041.54 million37.55 millionOptionable

Recent News About These Companies

ProPhase Labs Q1 2025 Earnings Preview
ProPhase Labs's Earnings Outlook
ProPhase Labs Delays Form 10-Q Filing
ProPhase Labs reports FY24 EPS ($2.61) vs (98c) last year

New MarketBeat Followers Over Time

Media Sentiment Over Time

Chimerix stock logo

Chimerix NASDAQ:CMRX

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Milestone Pharmaceuticals stock logo

Milestone Pharmaceuticals NASDAQ:MIST

$1.65 -0.02 (-1.20%)
Closing price 04:00 PM Eastern
Extended Trading
$1.66 +0.01 (+0.61%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Oramed Pharmaceuticals stock logo

Oramed Pharmaceuticals NASDAQ:ORMP

$2.12 +0.01 (+0.47%)
Closing price 04:00 PM Eastern
Extended Trading
$2.12 +0.00 (+0.24%)
As of 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

ProPhase Labs stock logo

ProPhase Labs NASDAQ:PRPH

$0.37 +0.00 (+0.38%)
Closing price 04:00 PM Eastern
Extended Trading
$0.38 +0.00 (+0.43%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.